about
Metronomic Chemotherapy--A New Path to Treat Advanced Non-small Cell Lung CancerMetronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistanceTracking the evolution of cancer cell populations through the mathematical lens of phenotype-structured equations.Future paradigms for precision oncologySchedule-Dependent Antiangiogenic and Cytotoxic Effects of Chemotherapy on Vascular Endothelial and Retinoblastoma CellsMetronomic oral cyclosphosphamide as third-line systemic treatment or beyond in patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma.Everolimus-based combination for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): biological rationale and critical review of published data.A Strategy to Delay the Development of Cisplatin Resistance by Maintaining a Certain Amount of Cisplatin-Sensitive Cells.Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan.Repurposing Drugs in Oncology (ReDO)-itraconazole as an anti-cancer agent.Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter studyTargeted therapy with propranolol and metronomic chemotherapy combination: sustained complete response of a relapsing metastatic angiosarcoma.Transcriptional profiling provides insights into metronomic cyclophosphamide-activated, innate immune-dependent regression of brain tumor xenograftsSmall-molecule BH3 mimetic and pan-Bcl-2 inhibitor AT-101 enhances the antitumor efficacy of cisplatin through inhibition of APE1 repair and redox activity in non-small-cell lung cancer.Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8(+) T-cell responses and immune memoryA phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol.Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators.Chemotherapy for Late-Stage Cancer Patients: Meta-Analysis of Complete Response Rates.Repurposing Drugs in Oncology (ReDO)-diclofenac as an anti-cancer agentCpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma modelHighlights from the 1st Latin American meeting on metronomic chemotherapy and drug repositioning in oncology, 27-28 May, 2016, Rosario, ArgentinaSH003 represses tumor angiogenesis by blocking VEGF binding to VEGFR2Clinical response in patients with ovarian cancer treated with metronomic chemotherapy.Nanometronomic treatment of 4T1 breast cancer with nanocaged doxorubicin prevents drug resistance and circumvents cardiotoxicity.Metronomics as maintenance treatment in oncology: time for chemo-switch.Akt targeting as a strategy to boost chemotherapy efficacy in non-small cell lung cancer through metabolism suppression.Metronomics chemotherapy: time for computational decision support.The emerging quest for the optimal angiostatic combination therapy.Angiogenesis in malignant melanoma.Metronomic Chemotherapy vs Best Supportive Care in Progressive Pediatric Solid Malignant Tumors: A Randomized Clinical Trial.Temozolomide-based combination for advanced neuroendocrine neoplasms: a systematic review of the literature.Clinical management of breast cancer heterogeneity.Clinical overview of metronomic chemotherapy in breast cancer.Targeting tumor vasculature: expanding the potential of DNA cancer vaccines.Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development.Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth.Angiogenesis in melanoma: an update with a focus on current targeted therapies.Tubulin inhibitors in non-small cell lung cancer: looking back and forward.Mathematical modeling for Phase I cancer trials: A study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients.Current achievements and future perspectives of metronomic chemotherapy.
P2860
Q27015786-FCDCD21F-F9A4-4965-81DF-4157B539C259Q27023579-0CA74882-F6E1-4FD9-AE3C-8DDB73E581B4Q27335464-CB882989-F950-403C-B799-FC1651292504Q28078745-2B9BD4A3-B40F-4DCD-A607-5C6CB5051C7BQ28553176-E8A3A379-A0CF-4174-ABC4-B85A85F1C72DQ30846827-14229738-287C-4808-86F6-B18A0FE1A827Q30884794-C16EB041-524A-4625-9C66-0E0D20E04BB7Q33671792-60ACB0D8-773C-4F69-9AA3-51F6B21BAD9BQ34173001-6EB4A260-9334-43A9-AF25-BAFAB4902EF4Q34474583-489E23C8-F136-4114-B4EC-0E69705BCA56Q34993605-82C11F5E-83CA-4FCA-946F-019120627EF6Q35002582-2BBAB44B-4EA0-4524-85DE-4C17E6797A4AQ35624661-DD1C5FAE-28AF-4669-B769-CE385205016BQ35743521-29E69FBC-C375-46FA-B06B-9F9342F458AEQ35799297-BEDD620F-05E3-492D-91BE-3B691362973DQ35994241-53EDDB10-5D82-41B5-80F8-7BB0B1904147Q36101917-10542B35-2E97-4831-832E-43F5731FDEA9Q36444444-9F46FCAA-83E1-41C3-A712-43F1E126E68CQ36483712-DB6C31A8-7B69-4272-854D-C5227E05C94BQ36600960-867DC2E2-1407-417C-828F-F3E9301FC35DQ37239002-470A2CC4-034C-4B2D-9116-52E1E4398313Q37362815-017A8B8B-DB6D-494F-9C75-5A899B154F9CQ37679904-F59167BB-6F34-498E-9788-12E17A990A32Q37702718-592E9709-1CDC-4A24-BA4F-A628008C5445Q37707573-3BC964A6-9D33-46AF-B692-113EF2770F8BQ37717138-735B330A-CE4C-4EA1-BE12-1DE5B9C7B0F6Q38235906-9FC77156-4510-4F1F-A8A9-CD6532B6AAA4Q38268453-E7F85D8D-5080-4E41-910D-7387ABB129AFQ38335946-EE5A7F75-9645-44E4-B8B5-0948B77C9FD6Q38378439-10375BDC-951C-4689-BB38-3E86CB4F6014Q38400485-FCA874BE-E9B6-49AE-BEA8-8F2D773D6C22Q38431284-90B052EE-D74E-4FF9-89C9-B51F77A19B78Q38560651-187768F7-73FC-49FE-95AF-21278ECF214BQ38565385-CDAD582E-6D08-443F-88D0-B867A8639283Q38638654-F0AC8220-8C30-4182-BA2F-66B9BCFEEDC9Q38722809-79739952-C106-499D-967F-A6E0590C3098Q38729125-E37F61B3-76D1-472E-A60C-28A847DE289CQ38742506-F361DDD4-4620-444E-80FA-146AAF4225C0Q38774653-BB53C120-4583-4B97-BB44-397B5F5AF1A7Q38788234-9F71BEB3-0AF2-434B-AEE1-23B462F33A17
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Metronomics: towards personalized chemotherapy?
@en
type
label
Metronomics: towards personalized chemotherapy?
@en
prefLabel
Metronomics: towards personalized chemotherapy?
@en
P2860
P1476
Metronomics: towards personalized chemotherapy?
@en
P2093
Manon Carré
Nicolas André
P2860
P304
P356
10.1038/NRCLINONC.2014.89
P407
P577
2014-06-10T00:00:00Z